RECURRENT B ACUTE LYMPHOBLASTIC LEUKEMIA
Clinical trials for RECURRENT B ACUTE LYMPHOBLASTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT B ACUTE LYMPHOBLASTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for RECURRENT B ACUTE LYMPHOBLASTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Engineered immune cells take on tough blood cancers in new trial
Disease control Recruiting nowThis early-stage trial tests a new type of cell therapy for people with certain blood cancers (like lymphoma and leukemia) that have returned or stopped responding to standard treatments. The therapy uses a patient's own immune cells, which are modified in a lab to better recogni…
Matched conditions: RECURRENT B ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Sumithira Vasu • Aim: Disease control
Last updated May 26, 2026 04:21 UTC
-
New combo therapy aims to stop relapsed leukemia in kids and young adults
Disease control Recruiting nowThis study tests whether adding nivolumab to blinatumomab works better than blinatumomab alone for children and young adults (ages 1 to 30) whose B-cell acute lymphoblastic leukemia (B-ALL) has returned after initial treatment. Participants include those with Down syndrome. The g…
Matched conditions: RECURRENT B ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:16 UTC
-
New combo therapy aims to tackle tough leukemia
Disease control Recruiting nowThis study tests a drug called inotuzumab ozogamicin, which targets and kills leukemia cells, combined with low-intensity chemotherapy. It is for adults with acute lymphoblastic leukemia (ALL), including those who are older or whose cancer has returned. The goal is to find the be…
Matched conditions: RECURRENT B ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 03:57 UTC
-
Engineered immune cells target tough childhood leukemia
Disease control Recruiting nowThis early-stage study tests a new type of immunotherapy for children and young adults up to age 21 whose leukemia has come back or not responded to treatment. The therapy uses the patient's own immune cells, which are modified in a lab to recognize and attack leukemia cells. The…
Matched conditions: RECURRENT B ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
New hope for tough leukemia: Triple-Drug combo enters human trials
Disease control Recruiting nowThis early-stage trial is testing a combination of three drugs (asparaginase, venetoclax, and blinatumomab) in adults whose B-cell acute lymphoblastic leukemia has returned or not responded to prior treatment. The study aims to find the safest dose and see how well the combinatio…
Matched conditions: RECURRENT B ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 22, 2026 13:51 UTC
-
New hope for kids with Tough-to-Treat leukemia: targeted therapy shows promise
Disease control Recruiting nowThis study tests a drug called inotuzumab ozogamicin in children and young adults (ages 1-21) whose B-cell acute lymphoblastic leukemia (B-ALL) has returned or not responded to standard treatment. The drug works like a smart bomb: it attaches to a protein (CD22) on leukemia cells…
Matched conditions: RECURRENT B ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated May 20, 2026 11:54 UTC
-
Promising combo tackles Hard-to-Treat leukemia in older patients
Disease control Recruiting nowThis study tests a two-drug combination for a type of leukemia (B-ALL) that is hard to treat, especially in older adults or when the cancer returns. The drugs work by targeting specific markers on cancer cells to kill them or stop their growth. The goal is to see if this approach…
Matched conditions: RECURRENT B ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 20, 2026 11:53 UTC